L-glutamine

About Emmaus Life Sciences

Emmaus Life Sciences is a biopharmaceutical company with a mission to develop and commercialize innovative therapies, initially for rare diseases. Its primary achievement is the 2017 FDA approval of Endari (L-glutamine oral powder) for sickle cell disease, establishing a commercial foundation. The company's strategy involves expanding Endari's global footprint, exploring its glutamine-based science in new indications like diverticulosis, and developing a novel cell sheet engineering platform. Recent leadership changes and a focus on financial improvement signal a period of strategic transition.

Therapeutic Areas